

REMARKS

Applicants thank the Examiner for discussing this application with the undersigned representative on April 5, 2005. In that interview, the Examiner indicated that she may be amenable to allowing claims reciting specific viral strains (HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 ROD, or SIV-1 MAC) if claims 49 and 50 were rewritten to incorporate the limitations of claims 27 and 28, respectively. The Examiner suggested canceling any claims not dependent from amended claims 49 and 50. Claims dependent from 49 and 50 recite specific viral strains and that the composition may further comprise a pharmaceutically acceptable vehicle (previously included in claims 32 and 33). Applicants have amended the claims as requested by the Examiner solely in an effort to facilitate prosecution.

In view of the foregoing remarks, Applicants respectfully request the reconsideration and reexamination of this application and the timely allowance of the pending claims.

If there is any fee due in connection with the filing of this paper, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 21, 2005

By: Rebecca McNeill
Rebecca M. McNeill
Reg. No. 43,796